Doctor of Osteopathy Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Badal Rana

Psychiatry Cherry Hill, NJ Doctor of Osteopathy

NPI 1013365931 CMS profile 7121941

2250 Chapel Ave W, Cherry Hill, NJ 08002

Open in the dashboard

General payments

$30

2 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Badal Rana of Cherry Hill, NJ is reported in the CMS Open Payments database as having received $30 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 12th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $15 1
2019 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Badal Rana
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Badal Rana were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Badal Rana Psychiatry median Middle half National median
2019 $15 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $15 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Masimo Corporation $15 1 payment
  2. Otsuka America Pharmaceutical, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $30 2 payments
Products named General payments · program years 2019–2021
  1. Patient SafetyNet System $15 1 payment
  2. ABILIFY MAINTENA $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

151

Median for Psychiatry & Neurology: 100

Drug cost

$47,109

Median for Psychiatry & Neurology: $2,986

Branded share of claims

32.5%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Versacloz Clozapine Brand 49 $43,635
Atropine Sulfate Generic 19 $1,079
Haloperidol Generic 24 $983
Olanzapine Generic 20 $627
Divalproex Sodium Generic 12 $390
Aripiprazole Generic 14 $320
Lamotrigine Generic 13 $75

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record